SIOP PNET5 MB trial: history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma
Background. SIOP PNET5 MB was initiated in 2014 as the first European trial using clinical, histological, and molecular parameters to stratify treatments for children and adolescents with standard-risk medulloblastoma. Methods. Stratification by upfront assessment of molecular parameters requires th...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2 December 2021
|
| In: |
Cancers
Year: 2021, Jahrgang: 13, Heft: 23, Pages: 1-16 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13236077 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers13236077 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/13/23/6077 
|
| Verfasserangaben: | Martin Mynarek, Till Milde, Laetitia Padovani, Geert O. Janssens, Robert Kwiecien, Veronique Mosseri, Steven C. Clifford, François Doz and Stefan Rutkowski |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1815690194 | ||
| 003 | DE-627 | ||
| 005 | 20230118162522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220902s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13236077 |2 doi | |
| 035 | |a (DE-627)1815690194 | ||
| 035 | |a (DE-599)KXP1815690194 | ||
| 035 | |a (OCoLC)1361714446 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mynarek, Martin |d 1980- |e VerfasserIn |0 (DE-588)139768912 |0 (DE-627)613094255 |0 (DE-576)313038295 |4 aut | |
| 245 | 1 | 0 | |a SIOP PNET5 MB trial |b history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma |c Martin Mynarek, Till Milde, Laetitia Padovani, Geert O. Janssens, Robert Kwiecien, Veronique Mosseri, Steven C. Clifford, François Doz and Stefan Rutkowski |
| 246 | 3 | 3 | |a SIOP PNET five MB trial |
| 264 | 1 | |c 2 December 2021 | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.09.2022 | ||
| 520 | |a Background. SIOP PNET5 MB was initiated in 2014 as the first European trial using clinical, histological, and molecular parameters to stratify treatments for children and adolescents with standard-risk medulloblastoma. Methods. Stratification by upfront assessment of molecular parameters requires the timely submission of adequate tumour tissue. In the standard-risk phase-III cohort, defined by the absence of high-risk criteria (M0, R0), pathological (non-LCA), and molecular biomarkers (MYCN amplification in SHH-MB or MYC amplification), a randomized intensification by carboplatin concomitant with radiotherapy is investigated. In the LR stratum for localized WNT-activated medulloblastoma and age <16 years, a reduction of craniospinal radiotherapy dose to 18 Gy and a reduced maintenance chemotherapy are investigated. Two additional strata (WNT-HR, SHH-TP53) were implemented during the trial. Results. SIOP PNET5 MB is actively recruiting. The availability of adequate tumour tissue for upfront real-time biological assessments to assess inclusion criteria has proven feasible. Conclusion. SIOP PNET5 MB has demonstrated that implementation of biological parameters for stratification is feasible in a prospective multicentre setting, and may improve risk-adapted treatment. Comprehensive research studies may allow assessment of additional parameters, e.g., novel medulloblastoma subtypes, and identification and validation of biomarkers for the further refinement of risk-adapted treatment in the future. | ||
| 650 | 4 | |a brain tumour | |
| 650 | 4 | |a children | |
| 650 | 4 | |a CNS | |
| 650 | 4 | |a medulloblastoma | |
| 650 | 4 | |a trial | |
| 700 | 1 | |a Milde, Till |d 1973- |e VerfasserIn |0 (DE-588)1038311837 |0 (DE-627)75711234X |0 (DE-576)39229334X |4 aut | |
| 700 | 1 | |a Padovani, Laetitia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Janssens, Geert O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kwiecien, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mosseri, Veronique |e VerfasserIn |4 aut | |
| 700 | 1 | |a Clifford, Steven C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Doz, François |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rutkowski, Stefan |d 1965- |e VerfasserIn |0 (DE-588)114616108 |0 (DE-627)527107506 |0 (DE-576)289803004 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 13(2021), 23, Artikel-ID 6077, Seite 1-16 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a SIOP PNET5 MB trial history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:23 |g elocationid:6077 |g pages:1-16 |g extent:16 |a SIOP PNET5 MB trial history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13236077 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/23/6077 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220902 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1038311837 |a Milde, Till |m 1038311837:Milde, Till |d 910000 |d 910500 |d 50000 |e 910000PM1038311837 |e 910500PM1038311837 |e 50000PM1038311837 |k 0/910000/ |k 1/910000/910500/ |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1815690194 |e 418431550X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 02.09.2022"],"titleAlt":[{"title":"SIOP PNET five MB trial"}],"relHost":[{"title":[{"title_sort":"Cancers","title":"Cancers"}],"language":["eng"],"pubHistory":["1.2009 -"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 27.05.2020"],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"text":"13(2021), 23, Artikel-ID 6077, Seite 1-16","extent":"16","volume":"13","pages":"1-16","issue":"23","year":"2021"},"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"2009-","dateIssuedKey":"2009","publisher":"MDPI"}],"id":{"eki":["614095670"],"issn":["2072-6694"],"zdb":["2527080-1"]},"disp":"SIOP PNET5 MB trial history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastomaCancers","recId":"614095670","name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]}}],"title":[{"subtitle":"history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma","title":"SIOP PNET5 MB trial","title_sort":"SIOP PNET5 MB trial"}],"person":[{"family":"Mynarek","role":"aut","given":"Martin","display":"Mynarek, Martin"},{"family":"Milde","given":"Till","role":"aut","display":"Milde, Till"},{"role":"aut","given":"Laetitia","family":"Padovani","display":"Padovani, Laetitia"},{"display":"Janssens, Geert O.","role":"aut","given":"Geert O.","family":"Janssens"},{"role":"aut","given":"Robert","family":"Kwiecien","display":"Kwiecien, Robert"},{"family":"Mosseri","role":"aut","given":"Veronique","display":"Mosseri, Veronique"},{"role":"aut","given":"Steven C.","family":"Clifford","display":"Clifford, Steven C."},{"display":"Doz, François","given":"François","role":"aut","family":"Doz"},{"display":"Rutkowski, Stefan","given":"Stefan","role":"aut","family":"Rutkowski"}],"physDesc":[{"extent":"16 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"2 December 2021","dateIssuedKey":"2021"}],"id":{"doi":["10.3390/cancers13236077"],"eki":["1815690194"]},"recId":"1815690194","name":{"displayForm":["Martin Mynarek, Till Milde, Laetitia Padovani, Geert O. Janssens, Robert Kwiecien, Veronique Mosseri, Steven C. Clifford, François Doz and Stefan Rutkowski"]}} | ||
| SRT | |a MYNAREKMARSIOPPNET5M2202 | ||